✦ LIBER ✦

Intensive chemotherapy in myelodysplastic syndromes

✍ Scribed by T.J Hamblin

Publisher: Elsevier Science
Year: 1992
Tongue: English
Weight: 603 KB
Volume: 6
Category: Article
ISSN: 0268-960X
DOI: 10.1016/0268-960x(92)90017-k

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Survival advantage with decitabine versu

Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome : Comparison with historical experience

✍ Hagop M. Kantarjian; Susan O'Brien; Xuelin Huang; Guillermo Garcia-Manero; Farha 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB

## Abstract ## BACKGROUND Decitabine, a hypomethylating agent, is active and has been approved for the treatment of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia. Intensive chemotherapy is an accepted form of therapy for patients with higher risk MDS. The comparative efficacy

Long-term follow-up results of the combi

Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome

✍ Hagop Kantarjian; Miloslav Beran; Jorge Cortes; Susan O'Brien; Francis Giles; Sh 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB

Intensive chemotherapy with idarubicin,

Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia

✍ W. K. Hofmann; G. Heil; C. Zander; S. Wiebe; O. G. Ottmann; L. Bergmann; K. Hoef 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 109 KB

Results of intensive chemotherapy in 998

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: : Predictive prognostic models for outcome

✍ Hagop Kantarjian; Susan O'Brien; Jorge Cortes; Francis Giles; Stefan Faderl; Eli 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 1 views

## Abstract ## BACKGROUND Elderly patients (age ≥ 65 years) with acute myeloid leukemia (AML) generally have a poor prognosis. AML‐type therapy results are often derived from studies in younger patients and may not apply to elderly AML. Many investigators and oncologists advocate, at times, only s

Aggressive chemotherapy in adult primary

Aggressive chemotherapy in adult primary myelodysplastic syndromes

✍ Fenaux, P. ;Lai, J. L. ;Jouet, J. P. ;Pollet, J. P. ;Bauters, F. 📂 Article 📅 1988 🏛 Springer-Verlag ⚖ 529 KB

Intensive chemotherapy for acute non-lym

Intensive chemotherapy for acute non-lymphoblastic leukemia after primary myelodysplastic syndrome

✍ Philippe Martiat; Augustin Ferrant; Jean-Louis Michaux; Gérard Sokal 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 435 KB

Twenty-five patients with a primary myelodysplastic syndrome (MDS) transformed into acute nonlymphoblastic leukaemia (ANL) were treated with intensive chemotherapy. A complete remission (CR) was obtained in six patients (24 per cent). In five of these six patients two courses of chemotherapy were ne